A5037150993- Malaria Research and Control
- Mosquito-borne diseases and control
- Parasites and Host Interactions
- HIV Research and Treatment
- Travel-related health issues
- Hepatitis B Virus Studies
- Infectious Diseases and Tuberculosis
- Mycobacterium research and diagnosis
- Vector-borne infectious diseases
- Complement system in diseases
- Tuberculosis Research and Epidemiology
- Diagnosis and treatment of tuberculosis
- Antibiotic Resistance in Bacteria
- Bacterial Identification and Susceptibility Testing
- vaccines and immunoinformatics approaches
- Enterobacteriaceae and Cronobacter Research
- Hepatitis C virus research
- Invertebrate Immune Response Mechanisms
- Influenza Virus Research Studies
- Helminth infection and control
- Obsessive-Compulsive Spectrum Disorders
- Gout, Hyperuricemia, Uric Acid
- Viral Infections and Outbreaks Research
- Smoking Behavior and Cessation
- T-cell and Retrovirus Studies
Sanaria
2018-2025
Fred Hutch Cancer Center
2024
United States Department of Defense
2020
Mike O'Callaghan Federal Medical Center
2018
United States Air Force
2018
Ralph H. Johnson VA Medical Center
2010-2017
Medical University of South Carolina
2008-2015
Naval Medical Research Command
1997-2002
Michigan State University
2000
University of Maryland, Baltimore
1997
During 1989–1999, 11 volunteers were immunized by the bites of 1001–2927 irradiated mosquitoes harboring infectious sporozoites Plasmodium falciparum (Pf) strain NF54 or clone 3D7/NF54. Ten first challenged Pf-infected 2–9 weeks after last immunization, and all protected. A volunteer 10 immunization was not Five previously protected rechallenged 23–42 a secondary 4 Two when with heterologous Pf (7G8). In total, there protection in 24 26 challenges. These results expand published findings...
Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus 7 P. falciparum genes inserted into its genome, was tested in phase I/IIa safety, immunogenicity, and efficacy vaccine trial human volunteers. Malaria the NYVAC genome encoded proteins from all stages of parasite's life cycle. Volunteers received three immunizations two different dosages NYVAC-Pf7. The safe well...
We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try reduce time and costs developing PfSPZ Vaccine prevent in Africa. Immunization with five doses at 0, 4, 8, 12, 20 weeks 2.7 × 105 gave 65% vaccine efficacy (VE) 24 against mosquito bite CHMI U.S. adults 52% (time event) or 29% (proportional) VE over naturally transmitted Pf Malian adults. assessed the...
Controlled human malaria infection (CHMI) by mosquito bite has been used to assess anti-malaria interventions in > 1,500 volunteers since development of methods for infecting mosquitoes feeding on Plasmodium falciparum (Pf) gametocyte cultures. Such CHMIs have never Africa. Aseptic, purified, cryopreserved Pf sporozoites, PfSPZ Challenge, were infect Dutch intradermal injection. We conducted a double-blind, placebo-controlled trial safety and infectivity Challenge adult male Tanzanians....
In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria's impact. Sanaria® PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated safe malaria-naïve experienced adults the United States Mali protective against controlled human infection with Pf field transmission Mali, but had not assessed...
Abstract Background A vaccine would be an ideal tool for reducing malaria’s impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1526 malaria-naive experienced 6-month to 65-year-olds the United States, Europe, Africa. When efficacy (VE) of 5 doses 2.7 × 105 was assessed adults against controlled human malaria infection (CHMI) States Tanzania intense field transmission...
ABSTRACT Plasmodium falciparum sporozoite (PfSPZ) Vaccine (radiation-attenuated, aseptic, purified, cryopreserved PfSPZ) and PfSPZ-CVac (infectious, PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria infection (CHMI) in nonimmune adults. sporozoite-CVac has never been assessed CHMI African vaccinees. We the safety, immunogenicity, VE three doses 2.7 × 10 6 at 8-week intervals 1.0 5...
Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria infection (CHMI) the same parasites as (homologous) than genetically distant (heterologous). We sought to identify an immunization regimen that similar VE CHMI homologous and heterologous Pf for at least 9 weeks malaria-naïve adults. Such a was identified part 1 (optimization), open label study, confirmed 2...
To determine the characteristics of clinical illness accompanying Plasmodium falciparum infection induced by controlled exposure to infected mosquitoes, records 118 volunteers participating in studies conducted between 1985 and 1992 were reviewed. One hundred fourteen (97%) reported at least one symptom attributable malaria, with fatigue, myalgias or arthralgias, headache, chills most commonly reported. The median duration symptoms was 3 days. Fever recorded 61% volunteers; 4 had...
Plasmodium falciparum sporozoite (PfSPZ) Vaccine is composed of radiation-attenuated, aseptic, purified cryopreserved PfSPZ. Multiple clinical trials empirically assessing two to six doses have shown multi-dose priming (two four the first week) be optimal for protection in both 4- and 16-week regimens. In this randomized, double-blind, normal saline (NS) placebo-controlled trial, groups (G) 18- 32-year-old Equatoguineans received regimens with or without a delayed final dose at 4 16 weeks....
BACKGROUND. Sanaria PfSPZ Vaccine, composed of attenuated Plasmodium falciparum (Pf) sporozoites (SPZ), protects against malaria. We conducted this clinical trial to assess the safety and efficacy Vaccine in HIV positive (HIV+) individuals since infection status participants mass vaccination programs may be unknown.
The whole Plasmodium falciparum sporozoite (PfSPZ) vaccine is being evaluated for malaria prevention. administered intravenously maximal efficacy. Direct venous inoculation (DVI) with PfSPZ has been safe, tolerable, and feasible in adults, but safety data children infants are limited.We conducted an age de-escalation, dose-escalation randomized controlled trial Siaya County, western Kenya. Children (aged 5-9 years, 13-59 months, 5-12 months) were enrolled into 13 age-dose cohorts of 12...
The World Health Organization (WHO) has called for new malaria vaccines with > 90% efficacy against Plasmodium falciparum infection to expand the anti-disease benefit provided by RTS,S/AS01 and R21/Matrix M subunit currently administered infants young children in sub-Saharan Africa. Attenuated P. sporozoites (PfSPZ) are being developed as a traveller's vaccine fulfill WHO's call high-level endemic countries support elimination. PfSPZ Vaccine, comprised of radiation-attenuated PfSPZ, was...
A malaria control program established in 2004 on Bioko Island, Equatorial Guinea, achieved significant reductions prevalence; however, progress subsequently stalled, leading to a proposal develop and implement highly effective vaccine increase impact. After conducting clinical trials of Sanaria® (Rockville, MD) Plasmodium falciparum ( P. ) sporozite vaccines against malaria, which demonstrated safety efficacy, larger phase 3 trial was planned support licensure for specific target populations...
Progress towards malaria elimination has stagnated, partly because infections persisting at low parasite densities comprise a large reservoir contributing to ongoing transmission and are difficult detect. This study compared the performance of an ultrasensitive rapid diagnostic test (uRDT) designed detect density conventional RDT (cRDT), expert microscopy using Giemsa-stained thick blood smears (TBS), quantitative polymerase chain reaction (qPCR) during controlled human infection (CHMI)...
The aerobic and anaerobic bacterial species their numbers were studied in tonsillar specimens from children who had undergone elective tonsillectomy: 6 patients with recurrent tonsillitis (RT), 9 hypertrophy (RTH), 8 obstructive (OTH). Mixed flora present all tonsils, yielding an average of 6.7 isolates (5.6 or facultative 1.1 bacteria). highest recovery rate organisms per tonsil was OTH (7.7 tonsil), compared to 6.3 RT 5.9 RTH. predominant Haemophilus influenzae (22 isolates), Neisseria sp...
Abstract Background PfSPZ vaccines comprising Plasmodium falciparum (Pf) sporozoites (SPZ) have demonstrated > 90% protection against variant Pf malaria infections for at least 12 weeks; they are the only with level of efficacy necessary to protect travellers. eukaryotic cells stabilized by cryopreservation and distributed using a cryogenic (below −150 °C) cold chain. The Ebola vaccine mRNA SARS-CoV-2 pioneered uptake requiring non-standard ultra-low temperature chains. chain liquid...
While prior research has shown differences in the risk of malaria infection and sickness between males females, little is known about sex vaccine-induced immunity to malaria. Identifying such could elucidate important aspects biology facilitate development improved approaches vaccination.Using a standardized enzyme-linked immunosorbent assay, IgG antibodies major surface protein on Plasmodium falciparum (Pf) sporozoites (SPZ), Pf circumsporozoite (PfCSP), were measured before two weeks after...
The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans multiple trials. Except for one, each trial restricted enrollment either infants children or adults < 50 years old. This was conducted Equatorial Guinea assessed the safety, tolerability, of three direct venous inoculations 1.8 × 106 2.7 PfSPZ, PfSPZ Vaccine, normal saline administered at 8-week intervals a randomized, double-blind,...
Abstract Background Extensive malaria control measures have been implemented on Bioko Island, Equatorial Guinea over the past 16 years, reducing parasite prevalence and malaria-related morbidity mortality, but without achieving elimination. Malaria vaccines offer hope for burden to zero. Three phase 1/2 studies conducted successfully Island evaluate safety efficacy of whole Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines. A large, pivotal trial radiation-attenuated Sanaria ® PfSPZ...